This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
New Immuno-Oncology Solutions (NIOS): Aligning Stakeholders in the Biotech Industry
Vroom, Govert; Maribel Berges; Sastre Boquet, IsaacCase SM-1701-EEntrepreneurship, Innovation and Change, StrategyThis case focuses on a small biotech company (NIOS), located in Barcelona, Spain, that is developing a new immune-oncology product for treating pancreatic cancer. The drug that the company is developing has recently finished Phase I of clinical trials successfully and is now preparing for Phase II and III. At this point, the CEO is approached by her former PhD director, a university professor, who asks if the company is interested in licensing a ...Starting at €8.20
-
Cómo lanzar nuevos productos para llegar al mercado de masas
Zunino, Diego; Grodal, Stine; Suarez, Fernando F.Article 75104Entrepreneurship, Innovation and Change, StrategyMuchas empresas fracasan en su intento de llegar al gran público porque no logran que su producto nuevo parezca novedoso y conocido al mismo tiempo. ¿Cómo combinar novedad y familiaridad para dejar atrás una posición de nicho?Starting at €8.20
-
New product launch strategy. Mix novelty and familiarity to move from niche to mainstream
Zunino, Diego; Grodal, Stine; Suarez, Fernando F.Article 75117Entrepreneurship, Innovation and Change, StrategyHelp your new product to “cross the chasm” and reach the “zone of adoption” with these practical tips.Starting at €8.20
-
New Immuno-Oncology Solutions (NIOS) - Teaching Note: Aligning stakeholders in the biotech industry
Vroom, Govert; Maribel Berges; Sastre Boquet, IsaacTeaching Note SMT-136-EEntrepreneurship, Innovation and Change, StrategyThis case focuses on a small biotech company (NIOS), located in Barcelona, Spain, that is developing a new immune-oncology product for treating pancreatic cancer. The drug that the company is developing has recently finished Phase I of clinical trials successfully and is now preparing for Phase II and III. At this point, the CEO is approached by her former PhD director, a university professor, who asks if the company is interested in licensing a ...Starting at €0.00